Management for severe Crohn's disease: a lifetime cost-utility analysis.
Jaisson-Hot
Isabelle
I
Hospices Civils de Lyon, Lyonn Cedex, France.
Flourié
Bernard
B
Descos
Louis
L
Colin
Cyrille
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000191:economics* / Q000628:therapy*; D013505:Digestive System Surgical Procedures / Q000191:economics; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D000069285:Infliximab; D008390:Markov Chains; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069285:Infliximab